Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of IncobotulinumtoxinA (Xeomin) in the Treatment of Glabellar Frown Lines
This study has been completed.
Study NCT00512135   Information provided by Merz Pharmaceuticals GmbH

First Received on August 6, 2007.   Last Updated on February 21, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Glabellar Lines
Additional drug interventions recognized in this trial
Botulinum Toxins
Botulinum Toxins, Type A
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Central Nervous System Agents
Neuromuscular Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Merz Pharmaceuticals GmbH


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services